NRx Pharmaceuticals, Inc. (NRXP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NRx Pharmaceuticals, Inc. (NRXP) closed at USD 2.59 on 2026-10-14, a change of -13.7 % over the past year, with a market capitalization of USD 117.33M.

NRx Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NRx Pharmaceuticals, Inc. key figures

Previous close

USD 2.59 (2026-10-14)

1-year change

-13.7 %

Market cap

USD 117.33M

Enterprise value

USD 91.39M

P/E ratio (trailing)

-4.93

P/E ratio (forward)

-7.74

EPS (trailing)

-0.55

EPS (forward)

-0.35

PEG ratio

n/a

Price to book

-677.50

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

15.10

Employees

29

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NRx Pharmaceuticals, Inc. and compare it with other stocks.